Chargement en cours...
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases low-density lipoprotein cholesterol (LDL-C) concentrations through interference with normal physiologic hepatic LDL receptor (LDLR) recycling. Inhibiting PCSK9 results in improved LDLR recycling, increased LDLR availability on hepatocyt...
Enregistré dans:
| Publié dans: | Vasc Health Risk Manag |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4868869/ https://ncbi.nlm.nih.gov/pubmed/27274264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S102564 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|